

"Thyroid dysfunction in Egyptian patients with systemic lupus erythematosus "

Thesis

Submitted

In partial Fulfillment of M.D.Degree in Rheumatology

By

Noran Osama Ahmed El-Azizi

M.D Internal Medicine, Ain Shams University

Under Supervision of

Prof. Dr. Mohamed Salah El-din Abd El-baky

Professor of Internal Medicine & Rheumatology

Faculty of Medicine, Ain Shams University

Prof. Dr. Dahlia Abdel-Mohsen Hussein

Professor of Internal Medicine & Rheumatology

Faculty of Medicine, Ain Shams University

Prof. Dr. Dalia Fayez Mohamed

Professor of Internal Medicine & Rheumatology

Faculty of Medicine, Ain Shams University

Prof. Dr. Howaida El Sayed Mansour

Professor of Internal Medicine & Rheumatology

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2014

"إحتلال وظيفة الغدة الدرقية فى مرضى الذئبة الحمراء المصريين"

رسالة مقدمة
من

د. / نوران أسامة أحمد العزى
دكتورة الباطنة العامة

توطئة للحصول على درجة الدكتوراه فى
الأمراض الروماتزمية

تحت اشراف

أ.د./محمد صلاح الدين عبد الباقي
استاذ الباطنة العامة و الأمراض الروماتزمية
بكلية الطب – جامعة عين شمس

أ.د./داليا عبد المحسن حسين
استاذ الباطنة العامة و الأمراض الروماتزمية
بكلية الطب – جامعة عين شمس

أ.د./داليا فايز محمد
استاذ الباطنة العامة و الأمراض الروماتزمية
بكلية الطب – جامعة عين شمس

أ.د./هويدا السيد منصور
استاذ الباطنة العامة و الأمراض الروماتزمية
بكلية الطب – جامعة عين شمس

كلية الطب
جامعة عين شمس

2014

ACKNOWLEDGEMENT

First of all thanks to god to whom I relate any success in achieving any work in my life.

I would like to express my sincere gratitude to Professor Dr. **MOHAMED SALAH EL-DIN ABDEL-BAKY**, professor of internal medicine, Faculty of Medicine, Ain Shams University for his kind supervision, continuous support and encouragement throughout this work.

I would like to express my great appreciation to Prof. Dr. **DAHLIA ABDEL-MOHSEN HUSSEIN**, Professor of internal medicine, Faculty of Medicine, Ain Shams University for her kind supervision, valuable advice, unlimited help and offering all the facilities for this work.

Acknowledgement

I would like to express my great thanks to **Prof. Dr. Dalia Fayz Mohamed**, Professor of internal medicine, Faculty of Medicine, Ain Shams University for her sincere help, precious remarks and continuous guidance.

I would also like to thank **Prof. Dr. Howaida El Sayed Mansour**, Professor of internal medicine, Faculty of Medicine, Ain Shams University for her valuable help in this work and precious remarks.

I would also like to thank **Dr Walaa MOHAMED**, Assistant lecturer of radiology, Faculty of Medicine, Ain Shams University for her valuable help in this work.

I am also grateful to **Dr. Moshera Sabry**, fellow of clinical pathology, Ain Shams University for her valuable unlimited help in this work.

Last but not least, I want to thank my great father & my great mother for their endless help and all my family members.

LIST OF CONTENTS

List of Abbreviations	III
List of Figures	VII
List of Tables	IX
Introduction	1
Aim of the Work	5
Review of Literature	7
Systemic Lupus Erythematosus	7
Endocrinal Manifestations Of SLE	65
Autoimmune Thyroid Disease	73
Subjects & Methods	123
Results	131
Discussion	157
Summary & Conclusion	175
Recommendations	181
References	183
Arabic Summary	

LIST OF ABBREVIATIONS

ACLE	Acute Cutaneous Lupus Erythematosus.
ACR	American College of Rheumatology.
ADs	Autoimmune Diseases.
AITD	Autoimmune thyroid Disease.
ALT	Alanine Aminotransferase.
ANA	Antinuclear Antibody.
Anti-dsDNA	Anti-double stranded DNA.
Anti-NMDA	Anti-N-Methyl D-Aspartate
Anti- β_2 GPI	Anti-Beta 2 Glycoprotein I.
Anti-Tg	Anti-thyroglobulin.
Anti TPO	Anti-thyroid peroxidase.
aPLs	Anti-phospholipids.
aPTT	Activated Partial Thromboplastin Time.
AST	Aspartate Aminotransferase.
AZA	Azathioprine.
BLys	B-lymphocyte stimulator.
BMI	Body Mass Index.
BUN	Blood Urea Nitrogen.
C2, C3 & C4	Complement 2, 3 & 4.
CCLE	Chronic Cutaneous Lupus Erythematosus.
CNS	Central Nervous System.
CPK	Creatin Phosphokinase.
CRP	C-reactive protein.
CS	Corticosteroids.
CSF	Cerebro Spinal Fluid.
CT	Computerized Tomography.
CTLs	Cytotoxic T Lymphocytes.
CVD	Cardiovascular Disease.
CYC	Cyclophosphamide.
DBP	Diastolic Blood Pressure.
DCs	Dendritic Cells.
DHEA	Dehydroepiandrosterone.
DLE	Discoid Lupus Erythematosus.
DM	Diabetes Mellitus.

List of Abbreviations

EBV	Epstein-Barr Virus.
ECG	Electrocardiogram.
EEG	Electroencephalogram.
ELISA	Enzyme Linked Immunosorbent Assay.
ESR	Erythrocyte Sedimentation Rate.
GFR	Glomerular Filtration Rate.
GI	Gastrointestinal.
GH	Growth Hormone.
Hb	Haemoglobin.
hCG	human Chorionic Gonadotropin.
HCQ	Hydroxychloroquine.
HDL	High Density Lipoprotein.
HLA	Human Leukocyte Antigens.
HPF	High Power Field.
HSCT	Haematopoietic Stem Cell Transplant.
IgG, IgM & IgA	Immunoglobulin G, M & A.
IL-6, IL-8 & IL-10,	Interleukin 6, 8 & 10.
ISN/ RPS	International Society of Nephrology/ Renal Pathology Society.
ITP	Idiopathic Thrombocytopenic Purpura.
IUD	Intrauterine Device.
LATS	Long- Acting-Thyroid Stimulating antibodies.
LDH	Lactate Dehydrogenase.
LDL	Low Density Lipoprotein
MMF	Mycophenolate Mofetil.
MRI	Magnetic Resonance Imaging.
MRS	Magnetic Resonance Spectroscopy.
MS	Metabolic Syndrome.
NIH	National Institutes of Health.
NPSLE	Neuropsychiatric lupus.
NSAIDs	Non Steroidal Anti-inflammatory Drugs.
OA	Osteoarthritis.
PET	Positron Emission Tomography.
PGA	Physician Global Assessment.
PPT	Postpartum thyroiditis.
PRL	Prolactin.
RBCs	Red Blood Cells.
RPR	Rapid Plasma Reagent.
SBP	Systolic Blood Pressure.

List of Abbreviation

SCLE	Subacute Cutaneous Lupus Erythematosus.
SLAM	Systemic Lupus Activity Score.
SLE	Systemic Lupus Erythematosus.
SLEDAI	Systemic Lupus Erythematosus Disease Activity Index
SLICC	Systemic Lupus International Collaborating Clinics Damage Index
SLS	Shrinking Lung Syndrome.
SNPs	Single- Nucleotide Polymorphisms.
SPECT	Single-photon Emission Computed Tomography.
SPF	Sun Protection Factor.
T4	Thyroxine.
TBG	Thyroxine-Binding Globulin.
TCR	T-Cell Receptor
TG	Triglyceride.
TGF β	Transforming growth factor β .
TG Ab	Thyroglobulin Antibodies.
TPO Ab	Thyroid Peroxidase Antibodies.
TPO	Thrombopoietin.
TSI	Thyroid-Stimulating Immunoglobulins.
TSH	Thyroid Stimulating Hormone.
TSHR/ TR Ab	Thyroid Stimulating Hormone Receptor Antibodies.
TNF α	Tumour necrosis factor α .
UV	Ultraviolet.
VAS	Visual analogue scale.
VDRL	Venereal disease research laboratory.
WBCs	White Blood Cells.
WHO	World Health Organization.

LIST OF TABLES

	Title	Page
Table 1	New and Confirmed Genetic Variants Conferring a Significant Risk of Systemic Lupus Erythematosus in Two Genome wide Association Studies	14
Table 2	Pathogenic Autoantibodies in Systemic Lupus Erythematosus	18
Table 3	Role of hormones in human SLE	23
Table 4	ACR classification for SLE	26
Table 5	SLICC Revision of the ACR Classification Criteria for SLE	29
Table 6	International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification of lupus nephritis	50
Table 7	Pathologic Features Used to Determine Activity and Chronicity Indices	52
Table 8	Biological therapies proposed for SLE treatment	59
Table 9	Classification of Autoimmune Thyroiditis	76
Table 10	Antibodies by biology, function, type and clinical use	78
Table 11	Clinical presentations of AITD	90
Table 12	Rheumatic manifestations of thyroid dysfunction	92
Table 13	Thyroid hormones & autoantibodies	102
Table 14	SLAM Score	125
Table 15	Descriptive data of Group I (Active SLE) & II (Inactive SLE) as regard duration of disease & treatment, dose & duration of drugs used and SLAM score.	132
Table 16	Descriptive data of Group I (Active SLE) & II (Inactive SLE) as regard different thyroid dysfunction symptoms.	133

List of Tables

	Title	Page
Table 17	Descriptive data of Group I (Active SLE) & II (Inactive SLE) as regard different thyroid dysfunction signs:	134
Table 18	Descriptive data of Group I (Active SLE) & II (Inactive SLE) as regard different measurements:	135
Table 19	Descriptive data of Group I (Active SLE) & II (Inactive SLE) as regard Laboratory investigations:	136
Table 20	Comparative study between Group I (Active SLE), II (Inactive SLE) & III (Control) as a regard thyroid function tests & antithyroid antibodies.	137
Table 21	Patients with thyroid dysfunction & antithyroid antibodies among Group I (Active SLE) & II (Inactive SLE) patients.	138
Table 22	Correlation between SLAM Score & different parameters	141
Table 23	Classification of the SLE patients in Group I (Active SLE) & II (Inactive SLE) according to thyroid functions & antibodies	142
Table 24	Comparative study between euthyroid, subclinical hypothyroidism & hypothyroidism among SLE patients as regard age, disease duration, duration of treatment & SLAM Score	146
Table 25	Descriptive data of euthyroid, subclinical hypothyroidism & hypothyroidism among SLE patients as regard different thyroid dysfunction symptoms	147
Table 26	Descriptive data of thyroid, subclinical hypothyroidism & hypothyroidism among SLE patients as regard different thyroid dysfunction signs	148
Table 27	Descriptive data of euthyroid, subclinical hypothyroidism & hypothyroidism among SLE patients as regard different measurements	149
Table 28	Comparative study between euthyroid, subclinical hypothyroidism & hypothyroidism among SLE patients as regard different laboratory investigations	150

List Of Tables

	Title	Page
Table 29	Comparative study between euthyroid, subclinical hypothyroidism & hypothyroidism among SLE patients as regard thyroid function tests & antithyroid antibodies	151
Table 30	Correlation between thyroid function tests, antibodies & different laboratory, measurements, disease duration, treatment duration and SLAM score among SLE patients	153

LIST OF FIGURES

	Title	Page
Figure 1	Interaction between a T Cell and an Antigen-Presenting Cell (APC)	15
Figure 2	T Cell -B Cell Interaction	15
Figure 3	Induction of surface Blebs during Apoptosis	21
Figure 4	Malar rash	32
Figure 5	Subacute cutaneous lupus erythematosus	32
Figure 6	Discoid lupus	33
Figure 7	Discoid alopecia	33
Figure 8	Lupus profundus.	34
Figure 9	Non scarring alopecia	35
Figure 10	Raynaud's phenomenon	36
Figure 11	Livedo reticularis	36
Figure 12	Oral ulcer	37
Figure 13	Pathogenesis of AITD.	81
Figure 14	Graves' disease. Varying degrees of manifestations of Graves ophthalmopathy	86
Figure 15	The gender among the different groups	131
Figure 16	Antithyroid antibodies among Group I (Active SLE), II (Inactive SLE) & Group III (Control).	139
Figure 17	Comparative study between Group I (Active SLE) & II (Inactive SLE) as regard Thyroid U/S:	140
Figure 18	Classification of the SLE patients in Group I (Active SLE) & II (Inactive SLE) according to thyroid functions & antibodies	143/144
Figure 19	Description of the SLE patients' gender according to thyroid functions	145
Figure 20	Descriptive data of euthyroid, subclinical hyperthyroidism & hypothyroidism and hypothyroidism groups among SLE patients as regard thyroid U/S	152

List of Figures

	Title	Page
Figure 21	Correlation between thyroid function tests, antibodies & different laboratory, measurements, disease duration, treatment duration and SLAM score among SLE patients	154/ 155/ 156